Literature DB >> 8126658

High-frequency testing techniques and instrumentation for early detection of ototoxicity.

S A Fausti1, R H Frey, J A Henry, D J Olson, H I Schaffer.   

Abstract

Veteran patients with certain types of infections and cancers are routinely treated with therapeutic agents having ototoxic potential, thus threatening loss of hearing sensitivity which preexists in the majority of these patients. To prevent communication deficits requiring intervention, this laboratory is developing instrumentation and techniques for early detection of ototoxicity. For this study, conventional (< or = 8 kHz) and high-frequency (> or = 8 kHz) hearing thresholds were monitored behaviorally in hospitalized veterans receiving treatment with ototoxic drugs. Data analysis revealed that monitoring only the high-frequency range would have identified 67% of ears showing change. A five-frequency range of hearing, specific to each individual, was identified for its high sensitivity to early ototoxic change. Monitoring of only these five frequencies in each patient would have identified 82% of ears that showed behavioral change. Auditory brainstem responses (ABR) were obtained in a subgroup using clicks and high-frequency (8-14 kHz) tone bursts. ABR latency/morphology changes were observed in 95% of ears demonstrating behavioral change. High-frequency tone-burst-evoked ABRs alone would have identified 93% of initial changes. Monitoring of high-frequency audition using these techniques shows promise for early detection of ototoxicity with potential for prevention of hearing loss in frequencies essential for verbal communication.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8126658

Source DB:  PubMed          Journal:  J Rehabil Res Dev        ISSN: 0748-7711


  9 in total

Review 1.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

2.  Evaluation of noise-induced hearing loss by reference to the upper limit of hearing.

Authors:  I Morioka; K Miyashita; Y Gowa; S Takeda
Journal:  Int Arch Occup Environ Health       Date:  1995       Impact factor: 3.015

3.  A Bayesian perspective on tinnitus pitch matching.

Authors:  Garnett P McMillan; Emily J Thielman; Krystyn Wypych; James A Henry
Journal:  Ear Hear       Date:  2014 Nov-Dec       Impact factor: 3.570

4.  The effect of Beta glucan on Cisplatin ototoxicity.

Authors:  Tuba Bayindir; Mustafa Iraz; Mehmet Kelles; Serdar Kaya; Mehmet Tan; Aliye Filiz; Yuksel Toplu; M Tayyar Kalcioglu
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2013-02-06

5.  Early Physiological and Cellular Indicators of Cisplatin-Induced Ototoxicity.

Authors:  Yingying Chen; Eric C Bielefeld; Jeffrey G Mellott; Weijie Wang; Amir M Mafi; Ebenezer N Yamoah; Jianxin Bao
Journal:  J Assoc Res Otolaryngol       Date:  2021-01-07

6.  Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort.

Authors:  Chelsea M Blankenship; Lisa L Hunter; M Patrick Feeney; Madison Cox; Lindsey Bittinger; Angela C Garinis; Li Lin; Gary McPhail; John P Clancy
Journal:  Am J Audiol       Date:  2021-01-19       Impact factor: 1.636

7.  An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal.

Authors:  Delicia Appana; Lavanithum Joseph; Jessica Paken
Journal:  S Afr J Commun Disord       Date:  2016-11-25

8.  Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.

Authors:  Karla Anacleto de Vasconcelos; Silvana Maria Monte Coelho Frota; Antonio Ruffino-Netto; Afrânio Lineu Kritski
Journal:  J Bras Pneumol       Date:  2018-04       Impact factor: 2.624

9.  High frequency audiometric study in cancer-cured patients treated with cisplatin.

Authors:  Elizabeth Oliveira Crepaldi de Almeida; Waléria Gama Umeoka; Rafaela Corcelli Viera; Ilmara Fátima de Moraes
Journal:  Braz J Otorhinolaryngol       Date:  2008 May-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.